Related Experiment Videos
Cyclin D1 expression in high-grade endometrial carcinomas--association with histologic subtype
R A Soslow1, P U Shen, M H Chung
1Department of Pathology, Weill Medical College, Cornell University-New York Presbyterian Hospital, USA.
Summary
Cyclin D1 expression is more common in endometrioid endometrial cancer (EC) than serous endometrial cancer (ESC), particularly in estrogen receptor-positive cases. This suggests distinct molecular pathways in poorly differentiated endometrial carcinomas.
Area of Science:
- Gynecologic Oncology
- Molecular Pathology
- Cell Cycle Regulation
Background:
- Endometrial endometrioid adenocarcinoma (EC) and endometrial serous carcinoma (ESC) are distinct subtypes with different risk factors, morphology, and outcomes.
- Cyclin D1 is a key regulator of the G1/S cell cycle transition.
- Estrogen receptors (ERs) and progesterone receptors (PRs) play roles in endometrial cancer development and progression.
Purpose of the Study:
- To investigate and compare the expression of cyclin D1, ER, and PR in EC and ESC matched for histological grade.
- To determine if cyclin D1 expression correlates with histological subtype (EC vs. ESC) and ER/PR status.
- To explore the potential link between cyclin D1 and ER/PR signaling pathways in endometrial cancer.
Main Methods:
- Immunohistochemical analysis of cyclin D1, ER, and PR expression.
- Study included 20 ESCs and 21 ECs, matched for histological grade.
- Archival, formalin-fixed, paraffin-embedded tissue samples were utilized.
Main Results:
- Cyclin D1 was expressed in 48% of ECs and 15% of ESCs (p = 0.02).
- ER expression was similar between EC (76%) and ESC (60%) (p > 0.05).
- ER-positive ECs showed a higher likelihood of cyclin D1 expression compared to ER-positive ESCs (p = 0.03), but no direct relationship was found within ECs. No significant relationship was observed between cyclin D1 and PR expression.
Conclusions:
- Cyclin D1 expression is significantly associated with endometrioid histology in poorly differentiated endometrial carcinomas.
- The findings support distinct pathobiological pathways between EC and ESC.
- Cyclin D1 may serve as a marker differentiating EC from ESC, especially in poorly differentiated tumors.